Cubist gets Dificid, tedizolid in deal for Optimer, Trius


With the deal for Optimer (OPTR), Cubist (CBST) gets the antibacterial drug Dificid, which it has co-promoted with OPTR since 2011. CEO Michael Bonney notes that the co-promotion experience combined with CBST's "outstanding hospital-based commercial infrastructure," should allow for the maximization of the drug's potential.

Previously, some worried disappointing Q1 Dificid sales ($16.8M versus estimates of ~$20M) would make OPTR less attractive as a takeout target.

In the Trius (TSRX) deal, CBST gets the antibiotic tedizolid phosphate (developed with Bayer outside the U.S.), a phase IV treatment for Gram-positive infections.

Comments (2)
  • whosez
    , contributor
    Comments (122) | Send Message
     
    Well, it sure seems like TSRX is letting the company go far too cheaply to me. Shareholders would have done much better if TSRX had gone ahead on its own.
    30 Jul 2013, 07:19 PM Reply Like
  • Rhinoish
    , contributor
    Comments (125) | Send Message
     
    Great for Cubist. Long both $CBST and $TSRX and very happy today.
    30 Jul 2013, 08:29 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs